Menu

APSARD conference

Dr. Goodman, panelist, 2020 Annual APSARD conference January 12, Washington DC

, , ,

Dr. David W. Goodman has been invited as a panelist to discuss clinical implications of adult ADHD research and the use of medications in complex treatment. APSARD, American Professional Society for ADHD and Related Disorders, is a nationally and internationally represented professional organization devoted to the advancement of ADHD education, research, and treatment. I have been a member of the Board of Directors for several years and now Co-chair for the Education Committee along with Dr. Len Adler at New York University.

I am honored to be invited this year as a panelist to discuss the clinical implications and translation of research to the care of patients. The title of the presentation “Plenary Session: Comparative Efficacy and Tolerability of ADHD Medications in Children/Adolescents and Adults: What is the Evidence and What Are the Implications for Guidelines, Algorithm Development, and Clinical Care“

The conference is open to all physicians and mental health professionals. Because of the scientific nature of the presentations, it is not open to the general public. The general public can take advantage of APSARD’s information by visiting www.adhdinadults.com for up to date and medically supported perspectives on diagnosis and treatment of ADHD in adults.

The APSARD conference this year will include representatives from the FDA to explore and understand the research review protocol to advance approval of proven effective medications.

Needless to say, in addition to caring for patients in my full time practice, I countinue to be actively involved with teaching/lecturing at continuing medical education conferences. Among other dates, I will be presenting at the Neuroscience Education Institute in Las Vegas in April 2020.

I advise my patients and their families to stay apprised of the current research and state of the art in diagnosis and effective treatments for ADHD. Don’t be fooled by marketing over research. Marketers will say “Let’s use it while it still works” meaning, once research investigates it, it may be nothing more than placebo. This couldn’t be more true then in the nutriceutical supplements for ADHD and memory. But that’s a discussion for another time.

Thank you for your time.

David W. Goodman, M.D., LFAPA

Faculty speaker, annual American Professional Society for ADHD and Related Disorders conference

, , , , , , , , , , , ,

American Professional Society for ADHD and Related Disorders (APSARD) is an organization founded by a national and international group of experts in ADHD treatment and research. The annual meeting, “ADHD Advances: Challenges and Opportunities” being held September 27 – 28, 2013 at the Hyatt Regency Washington on Capitol Hill in Washington, DC  brings together these experts and other professionals interested in learning and advancing their skills. The presentations are the cutting edge research, treatment options, and technology developments to further our understanding of ADHD and the co-existing psychiatric and medical disorders.  Information and discussions extend beyond U.S. research to include Canadian, European and Middle East research and treatments.

I am honored to be invited to present a 60 minute workshop on the “Choice and Optimal Dosing of Medications for Adults with ADHD” with my co-presenter Dr. Janet Standard, a psychiatric Advanced Practice Nurse at the NYU Health Services. 

The conference is open to professionals in the health care field and registration is available now. . this link, you can browse the conference agenda, location, and hotel accommodations. This is a top-level, relatively small conference that allows all participants to engage and exchange thoughts and ideas. If you are in the field of ADHD, this is a conference not to miss. See you there.

David W. Goodman, M.D.